<DOC>
	<DOCNO>NCT02670915</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety faster-acting insulin aspart compare NovoRapid® combination insulin degludec child adolescent type 1 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Faster-acting Insulin Aspart Compared NovoRapid® Both Combination With Insulin Degludec Children Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Male female , 1 year equal age 18 year time signing inform consent 18 year time randomisation Diagnosed type 1 diabetes mellitus ( base clinical judgement support laboratory analysis per local guideline ) Ongoing daily treatment basalbolus insulin regimen use basal insulin analogue NPH insulin least 90 day prior screen visit HbA1c ( glycosylated haemoglobin ) equal 9.5 % ( 80 mmol/mol ) analyse central laboratory screen visit More one episode diabetic ketoacidosis require hospitalisation within last 90 day prior screen visit Treatment medication indication diabetes obesity state inclusion criterion period 90 day screen</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>